SMO and breast cancer: Several other SMO inhibitors have also entered clinical trials to evaluate their therapeutic effects on BCC, pancreatic cancer, colon cancer, and breast cancer.538 However, clinical studies of some drugs, such as saridegib (a cyclopamine analog), TAK-441, IPI-926, and CUR-61414, have been terminated due to detrimental effects and lack of response.539 It is worth mentioning that the FDA-approved antifungal drug itraconazole was found to have an inhibitory effect against the HH pathway by antagonizing SMO.